The Royal Science Academy of Sciences has decided to award the 2017 Crafoord Prize in Polyarthritis to
Shimon Sakaguchi, Osaka University, Japan,
Fred Ramsdell, Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
Alexander Rudensky, Memorial Sloan Kettering Cancer Center, New York, NY, USA,
"for their discoveries relating to regulatory T cells, which counteract harmful immune reactions in arthritis and other autoimmune diseases."
Autoimmune diseases arise when the body's immune system malfunctions, attacking normal tissue. Globally, these diseases cause great suffering and premature death for millions of people. Autoimmune diseases include multiple sclerosis (MS), type 1 diabetes and polyarthritis. The latter is a term used for rheumatic diseases in which multiple joints are affected.
There are great hopes that highly effective treatments for autoimmune diseases will be possible, based on new knowledge about the immune system that was gained over the last few decades. Three researchers are now being rewarded for their fundamental discoveries in the field: Shimon Sakaguchi, Fred Ramsdell, and Alexander Rudensky.
The Laureates' discoveries relate to regulatory T cells, which are the immune system's security guards. Their task is to keep an eye on other white blood cells that are overzealous in their task of defending the body from intruders and could harm things they should leave alone, such as healthy cells in joints, the pancreas or brain.
Even back in the 1960s, researchers were searching for suppressor cells in the immune system, but the research results were contradictory. Accordingly, over time, the consensus became that no such cells existed. Despite this, Shimon Sakaguchi persevered with the search and, after many years, he succeeded in identifying the cells that are now called regulatory T cells. Some years later, Fred Ramsdell approached the same area from a different direction; he isolated and identified the gene that is linked to severe autoimmune disease in a particular strain of mice. He also demonstrated that mutation in the same gene in humans, now known as FOXP3, causes a severe congenital disease called IPEX. Shortly afterwards, decisive findings were made, linking these two pieces of knowledge together. Alexander Rudensky, Shimon Sakaguchi and Fred Ramsdell each described how the FOXP3 gene is vital to a process that results in some T cells becoming security guards in the immune system. These are the regulatory T cells, which can prevent autoimmune reactions because they detect and suppress overzealous colleagues in the immune system.
A great number of clinical trials are now being conducted globally, with research teams testing various ways of using regulatory T cells to subdue the immune system's attacks that cause autoimmune diseases. The long-term vision is that of a breakthrough in the treatment of polyarthritis and other autoimmune syndromes, which could be treated more effectively than they are today.
Additional information, a video about this year's prize and illustrations for editorial use are available at:
This year's Crafoord Prize
The Crafoord Prize is awarded as a partnership between the Royal Swedish Academy of Sciences and the Crafoord Foundation in Lund. The Royal Swedish Academy of Sciences is responsible for deciding upon the Crafoord Laureates.
The prize is awarded in one discipline each year, according to a set schedule for Mathematics and Astronomy, Geosciences, and Biosciences. The prize for Polyarthritis is awarded only when a special committee has demonstrated that scientific progress in this field has been such that an award is justified.
The prize amount is 6 million Swedish krona to be shared equally between the Laureates.
The award ceremony will be held at the Royal Swedish Academy of Sciences on 18 May 2017, in the presence of H.R.H. Crown Princess Victoria.
The Crafoord Days are 15-18 May 2017 in Stockholm and Lund. A detailed programme will be available at http://kva.se/events
Prize lecture: 16 May, Lund University.
Prize symposium: 17 May, Stockholm. Please register via http://kva.se/events
Prize ceremony: 18 May, Beijer Hall, Royal Swedish Academy of Sciences, Stockholm.
Shimon Sakaguchi, Professor at Osaka University, Japan. Discovered and documented the occurrence of regulatory T cells by systematically investigating cells that develop in the thymus of young mice, in a series of experiments from 1985 onwards. Born 1951.
Fred Ramsdell, Head of Research at Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Identified the faulty gene in some mice and children that are born with IPEX, a severe autoimmune disease, in 2001. This gene, FOXP3, has proven to be vital in the development of regulatory T cells. Born 1961.
Alexander Rudensky, Professor, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Knocked out the FOXP3 gene in mice in 2003, so they were unable to form regulatory T cells and thus suffered from severe autoimmune diseases. At about the same time, Sakaguchi and Ramsdell independently presented evidence that FOXP3 governs the formation of regulatory T cells and, at a stroke, a dynamic new field of research arose. Born 1956.
More information about the Crafoord Prize
Klas Kärre, Professor of Molecular Immunology,
Crafoord Prize Committee
Tel: +46 8 524 862 82
Olle Kämpe, Professor of Clinical Endocrinology,
Crafoord Prize Committee
Tel: +46 70 815 1400
Jessica Balksjö Nannini, Press Officer,
Royal Swedish Academy of Sciences
Tel: +46 70 673 9650
This information was brought to you by Cision http://news.cision.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/this-years-crafoord-prize-is-awarded-for-fundamental-discoveries-in-immune-regulation-300390010.html
Related medicine technology :
1. Phosphate Binder Use Has Declined Over the Past Two Years in the U.S. Dialysis Setting, While Sensipar Use in Hemodialysis has Declined Since Last Year
2. Celebrating 25 Years and Counting: Leukemia and Lymphoma Societys "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients
3. West to Celebrate 90 Years of Healthcare Innovation at the NYSE
4. Alex Rodriguez Should Spend the Next Two Years Talking to Our Youngest Steroids Users
5. French Man with SynCardia Total Artificial Heart Surpasses Two Years of Support
6. Sanofi Pasteurs Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older
7. 50 Years Old and Still Bounding Over the Counter: Klines Healthcare Practice Continues to Deliver Unmatched OTC Market Intelligence
8. Turkey Businessman, Two Years Without a Human Heart, Goes Four-Wheeling
9. Stage at Breast Cancer Diagnosis Will Shift Dramatically Over the Next 20 Years in Key Latin American Markets
10. 3D Mammography (Breast Tomosynthesis) - Hottest Clinical Procedure Four Years in a Row
11. Drug Use Among American Workers Declined 74% Over Past 25 Years, Finds Unprecedented Analysis of More Than 125 Million Workplace Urine Drug Tests